Endo upgraded to outperform by RBC

RBC Capital markets analyst Ken Trbovich moved Endo Pharmaceuticals Holdings, Inc. to outperform from sector perform, with above average risk and $40 price target based on the long-term potential from Opana's approval. Opana's launch puts the company on track to earn above $2 per share in 2007 and between $2.30 and $2.50 in 2008. Shares of the Chadds Ford, Pa.-based pharmaceutical company were up 31 cents, or 0.98%, at $31.81 on volume of 2,958,874 shares versus the three-month running average of 1,151,270 shares. (Nasdaq: ENDP)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.